Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.38 |
| ▸ | KCNN3 | Q9UGI6 | 8/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.31 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864163 | 1.00 | PIK3CD (0.38) | PIK3CDKCNN3PIK3R1KDM4EIRAK4 | |
| SCHEMBL863593 | 0.88 | KCNN3 (0.38) | PIK3CDKCNN3PIK3R1KDM4EKCNN1 | |
| SCHEMBL863594 | 0.88 | KCNN3 (0.38) | PIK3CDKCNN3PIK3R1KDM4EKCNN1 | |
| SCHEMBL863650 | 0.79 | IRAK1 (0.39) | PIK3CDKCNN3PIK3R1IRAK4 | |
| SCHEMBL863649 | 0.79 | IRAK1 (0.39) | PIK3CDKCNN3PIK3R1IRAK4 | |
| SCHEMBL864458 | 0.76 | MAP4K4 (0.44) | PIK3CD | |
| SCHEMBL864459 | 0.76 | MAP4K4 (0.44) | PIK3CD | |
| SCHEMBL864075 | 0.76 | PIK3CD (0.41) | PIK3CDKDM4ETNF | |
| SCHEMBL864074 | 0.76 | PIK3CD (0.41) | PIK3CDKDM4ETNF | |
| SCHEMBL2115716 | 0.76 | PIK3CD (0.35) | PIK3CDKCNN3PIK3R1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885KCNN3 1241/4885PIK3R1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.